Mavrilimumab is a humanized monoclonal antibody targeting granulocyte macrophage colony-stimulating factor receptor (GM-CSF-R). Mavrilimumab has been investigated for the treatment of rheumatoid arthritis.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.